This site and its domain are for sale. Email the owner if you want to talk about it.

bariatricalt.com

Endoscopic Revision After Bypass: TORe and Friends

TORe tightens one stretched hole in a bypass, and the evidence for how well it works is thinner than the hole.

Illustration of a small stomach pouch joined to the intestine through a narrow outlet, with an endoscope approaching from above.

Here is a small fact about gastric bypass: the part that does most of the work is a hole. After the operation, food leaves a small stomach pouch through a narrow connection into the intestine, and that connection (surgeons call it the outlet, or the gastrojejunal anastomosis, which is the same hole with more syllables) is supposed to stay narrow. Sometimes it stretches. When it does, food moves through faster, and some patients regain weight.

The tore procedure, which is how most people type it and which the literature writes as TORe, for transoral outlet reduction, is the proposed fix: a doctor goes in through the mouth with an endoscope and sews the stretched outlet smaller again. That is what it is. How much weight it takes back off, and for how long, is a harder question, and the evidence gathered for this article contains no TORe trial result, so on the numbers the honest answer is that it is not settled here. What the evidence does settle is the shape of the problem TORe is meant to solve, and that shape is mostly about who gets paid for which procedure, and when.

What the TORe procedure actually is

Read the name literally. Transoral: through the mouth. Outlet: the exit from the stomach pouch. Reduction: smaller. (Medicine names things the way a contract defines terms, which is to say completely and with no jokes.) It belongs to the same family as endoscopic sleeve gastroplasty, which one narrative review describes as creating a sleeve “through endoscopic suturing to create a tubular gastric sleeve without resection, preserving native anatomy.” Same tools, different target. ESG sews a normal stomach into a tube; TORe sews a bypass outlet back down to size.

The “friends” in the title are the other revisions done this way, for instance resuturing a sleeve gastrectomy that has stretched out over the years. These sit on this site’s ground for revision specifically. Their outcome numbers are not in the source list either. That absence is sort of the point of this article, and we will come back to it.

Who gets paid for the first operation, and what that costs later

Start the chain at the first link. A surgeon performs a primary operation and is paid for it, and the most common one is the sleeve: one comparative study states flatly that “Sleeve gastrectomy is currently the most performed bariatric procedure worldwide.” A long-term review put weighted mean total weight loss at 10 years at 24.4% for the sleeve, rising to about 40% for the duodenal switch. The operation works. It also does not always stay working.

The Polish BARI-10-POL study followed 485 patients, 317 of whom (65.4%) had a sleeve as their first operation. Over 10 years, 23.9% of patients needed a revisional procedure, “most commonly after sleeve gastrectomy (24.3%) and adjustable gastric banding (100%).”

That last figure deserves to be entered into the record with appropriate gravity. A revision rate of 100% means that every member of the relevant class was revised, without exception, over the period of observation, such that a band patient who was not revised would constitute a finding in itself and would presumably merit a paper of her own. The band has its own article on this site. The band is not doing well (this is the polite version).

Second link: a patient regains weight, and the obvious next step is a second operation, which someone is also paid for. Here is how a Frontiers review of endoscopic management puts the trouble with that: surgical revision and conversion “are associated with higher morbidity and mortality compared to the primary surgical intervention.” Translated into a flat sentence: the second operation is more dangerous than the first one. The scar tissue is already there.

Why convert, repair, or medicate after a sleeve or bypass

If a second operation is happening anyway, the question is which one. After a sleeve, the choices on offer include conversion to a Roux-en-Y bypass, to a one-anastomosis gastric bypass (OAGB), or to SADI. A seven-year study of conversions found OAGB produced greater total weight loss and BMI reduction than Roux-en-Y at both 1 and 7 years. A meta-analysis of SADI versus OAGB as revisions found excess weight loss did not differ at two years, but total weight loss stayed higher with SADI. To be fair, these are different patients in different hospitals, and nobody randomized anyone.

Then there is the third option, which does not involve an operating room at all. A multicenter retrospective study compared sleeve patients converted to bypass against sleeve patients who stayed put and added a GLP-1 drug. HbA1c control showed no significant difference between the groups at any time point. On the other hand, the conversion group started with a higher HbA1c (6.19 versus 5.85), which tells you something about who gets sent to surgery. Both groups also reportedly weighed about 242 kilograms at baseline (a figure that looks a lot like a units column having a long day).

A randomized trial, BARI-STEP, enrolled adults at least a year after bypass or sleeve with what it calls “a suboptimal clinical response” and tested semaglutide against placebo. That phrase is clinical language for: the operation did less than everyone hoped. The source list here gives the trial’s design but not its results, so those are not settled in this article.

Why a bypass might be worth repairing rather than replacing

This is where TORe’s logic comes from. A bypass, even a stretched one, seems to keep doing something. One report on long-term bypass patients found that even those who regained 100% or more of their lost weight kept type 2 diabetes in remission in about 60% of cases, which the authors read as a weight-independent benefit from bypassing the duodenum. The Oseberg trial, which randomized 109 people with diabetes between 2012 and 2017, found 5-year remission of 63% after bypass versus 30% after sleeve, and total weight loss of 22.2% versus 17.2%. It also found pathological acid reflux more often after the sleeve, while symptomatic low blood sugar after meals was more common after bypass (28% versus 2%).

So picture a surgeon looking at a regained bypass patient and saying, “Look, the plumbing is fine. It’s the faucet.” If the rerouting still earns its metabolic keep, then tightening one hole from the inside is a smaller bet than tearing the whole thing up. That is the pitch, anyway. Whether the tightened hole stays tight is exactly the number this list does not have.

What the evidence does not tell us yet

The endoscopic procedures have revision rates of their own. In a six-year ESG cohort of 1,377 patients, 5.7% needed revision. ESG’s 12-month total weight loss runs 13% to 16%, according to one review, with outcomes sustained up to 3 years. These are smaller, gentler procedures with smaller, gentler results, which is a reasonable trade, but they are also procedures that sometimes get redone.

Here is a made-up scenario, clearly invented. A patient gets a bypass at 40. The outlet stretches; she gets a TORe at 47. It stretches again; another at 53. By 80 her outlet has been resewn so many times that it has more stitching than a baseball, the endoscopist knows it better than his own kitchen, and the procedure has quietly become a subscription billed every six years. Does anyone want that? Probably not. But nothing in the payment structure obviously stops it either.

For what it is worth, writing about this means reading hundreds of abstracts to report that the most interesting procedure has the least data, which I guess is a job description. The chain runs from a surgeon paid for a first operation, to a riskier second operation, to an endoscopist paid for a sewing job through the mouth, to a drug that might make the sewing unnecessary, and at the end of it nobody planned for the fate of a lot of people to rest on the diameter of one hole.

It is a very small hole, and it matters a lot.

Sources

  1. Endoscopic Sleeve Gastroplasty: 6-Year Outcomes in 1,377 Patients
  2. Frontiers | Endoscopic Management of Weight Recurrence Following Bariatric Surgery
  3. Endoscopic Sleeve Gastroplasty: A Qualitative Narrative Review of Outcomes, Safety, and Clinical Applications
  4. Sleeve-to-bypass conversion vs. sleeve-with-adjuvant GLP-1 receptor agonists: an academic multicenter retrospective study
  5. Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial.
  6. Shaping the Future of Restrictive Bariatric Surgery: Clinical, Economic, and Long-Term Perspectives on Endoscopic and Laparoscopic Sleeve
  7. Seven-Year Comparative Outcomes of One Anastomosis Gastric Bypass and Roux-en-Y Gastric Bypass for Weight Recurrence Regain Post Sleeve Gastrectomy
  8. A Comprehensive Review of Sleeve Gastrectomy, Roux-en-Y Gastric Bypass, One-Anastomosis Gastric Bypass, Duodenal Switch, and SADI-S: Very Long-Term Outcomes at 10 Years and Beyond
  9. Long-term outcomes of metabolic bariatric surgery: a 10-Year multicenter retrospective study in Poland (BARI-10-POL)
  10. Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial
  11. Scholars@Duke publication: Patient-reported outcomes, weight loss, and remission of type 2 diabetes 3 years after gastric bypass and sleeve gastrectomy (Oseberg); a single-centre, randomised controlled trial.
  12. Laparoscopic Single Anastomosis Duodeno-Ileal Bypass Versus One Anastomosis Gastric Bypass as Revisional Procedures after Sleeve Gastrectomy: Meta-analysis and Systematic Review
  13. Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial
  14. Gastric Bypass Improves Long-Term Diabetes Remission, Even After Weight Recurrence | ACS
  15. Continued Diabetes Remission Despite Weight Recurrence: Gastric Bypass Long-Term Metabolic Benefit.

Bariatric Alt explains published research. It is not medical advice, and it never recommends a surgeon, a clinic, a dose or a product. Talk to a clinician about which option fits you.

Read next